Small Airway Obstruction in Asthma, COPD, ACOS
Comparative Study on Sputum Anti-inflammatory Mediators in Patients With Asthma or Asthma and COPD Overlap (ACOS) Syndrome, and COPD
1 other identifier
observational
230
1 country
1
Brief Summary
This study was designed as retrospective chart review to test our hypothesis whether there are the differences in inflammatory and anti-inflammatory mediators between asthmatic and ACOS patients with small airway obstruction, and COPD
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 10, 2018
CompletedFirst Submitted
Initial submission to the registry
January 30, 2018
CompletedFirst Posted
Study publicly available on registry
February 6, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedJune 18, 2024
June 1, 2024
2.6 years
January 30, 2018
June 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Lipoxin A4, ,
Lipoxin A4 is measured in sputum supernatants by ELISA
1 day (single time point)
Secondary Outcomes (2)
IL-33
1 day (single time point)
Thymic stromal lymphopoietin (TSLP)
1 day (single time point)
Study Arms (4)
Asthma with SAO+
Asthmatic patients with RV/TLC \> or = 40
Asthma with SAO-
Asthmatic patients with RV/TLC \< 40
ACO
Asthmatic patients with smoking \> or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC \< 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 \> or = 200 ml and FEV1% \> or =12% after BD)
COPD
Patients with history of smoking \> or = 10 pack year with post-BD FEV1/FVC \< 0.7 and negative BD reversibility (absolute increase in FEV1 \< 200 ml and FEV1% \<12% after BD)
Interventions
No any intervention is applied to any groups in this study
Eligibility Criteria
Participants recruited from Asthma Clinics and OPD in Siriraj Hospital
You may qualify if:
- Physician-diagnosed asthma, ACO, and COPD
- Their spirometric, IOS, lung volume, demographic data and sputum samples are available
You may not qualify if:
- Concomitant diseases requiring immunosuppressive therapy
- Being on treatments with NSAIDs, macrolides, statins
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Siriraj Hospital
Bangkok Noi, Bangkok, 10700, Thailand
Biospecimen
Sputum cell pellets, sputum supernatants, and sputum cytospins
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kittipong Maneechotesuwan, MD, PhD
Siriraj Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 30, 2018
First Posted
February 6, 2018
Study Start
January 10, 2018
Primary Completion
July 31, 2020
Study Completion
December 31, 2020
Last Updated
June 18, 2024
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will not share